PDF herunterladen
Klin Monbl Augenheilkd 2016; 6(03): 227-241
DOI: 10.1055/s-0042-109874
Grundlagen
Georg Thieme Verlag KG Stuttgart · New York

Lymphomerkrankungen des Auges

Ocular Lymphomas
Vinodh Kakkassery
Klinik für Augenheilkunde, Universitätsklinikum Knappschaftskrankenhaus Bochum – Ruhr-Universität Bochum
,
Marc Ilan Wunderlich
Klinik für Augenheilkunde, Universitätsklinikum Knappschaftskrankenhaus Bochum – Ruhr-Universität Bochum
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
05. August 2016 (online)

Auch verfügbar auf
    Lizenzen und Reprints Alle Artikel dieser Rubrik

Siehe auch:

Lymphomerkrankungen des AugesKlin Monbl Augenheilkd 2016; 233(10): 1175-1191
DOI: 10.1055/s-0033-1358243

Lymphome sind maligne Entartungen des lymphatischen Systems. Sie können sowohl systemisch auftreten als auch isoliert das Auge betreffen und sind als potenziell lebensbedrohliche Erkrankung anzusehen. Ziel des Artikels ist es, eine Übersicht zum komplexen Krankheitsbild der okularen Lymphome zu geben und ein evidenzbasiertes Schema zur diagnostischen und therapeutischen Vorgehensweise sowie zur engmaschigen Nachkontrolle mit psychoonkologischer Betreuung zu präsentieren.

 

  • Literatur

  • 1 Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Genf: World Health Organization; 2008
    Google Scholar
  • 2 Klinke R, Bauer C, Silbernagl S. Lehrbuch der Physiologie. Stuttgart: Thieme; 2003
    Google Scholar
  • 3 Sarkozy C, Traverse-Glehen A, Coiffier B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol 2015; 16: e555-e567
    CrossrefGoogle Scholar
  • 4 Armitage JO, Coiffier B, Dalla-Favera R. Non-Hodgkin Lymphomas. Alphen aan den Rijn: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009
    Google Scholar
  • 5 Chaudhary RK, Bhatt VR, Vose JM. Management of extranodal natural killer/t-cell lymphoma, nasal type. Clin Lymphoma Myeloma Leuk 2015; 15: 245-252
    CrossrefGoogle Scholar
  • 6 Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkinʼs Disease Staging Classification. Cancer Res 1971; 31: 1860-1861
    Google Scholar
  • 7 Rath S, Connors JM, Dolman PJ et al. Comparison of American Joint Committee on Cancer TNM-based staging system (7th ed.) and Ann Arbor classification for predicting outcome in ocular adnexal lymphoma. Orbit 2014; 33: 23-28
    CrossrefGoogle Scholar
  • 8 Coupland SE, White VA, Rootman J et al. A TNM-based clinical staging system of ocular adnexal lymphomas. Arch Pathol Lab Med 2009; 133: 1262-1267
    Google Scholar
  • 9 Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa. Blood 2009; 114: 501-510
    CrossrefPubMedGoogle Scholar
  • 10 Freemann E. [Nursing research]. Osterr Krankenpflegez 1974; 27: 293-295
    Google Scholar
  • 11 Moslehi R, Devesa SS, Schairer C et al. Rapidly increasing incidence of ocular non-hodgkin lymphoma. J Natl Cancer Inst 2006; 98: 936-939
    CrossrefGoogle Scholar
  • 12 Andrew NH, McNab AA, Selva D. Review of 268 lacrimal gland biopsies in an Australian cohort. Clin Experiment Ophthalmol 2015; 43: 5-11
    CrossrefGoogle Scholar
  • 13 Andreoli MT, Aakalu V, Setabutr P. Epidemiological trends in malignant lacrimal gland tumors. Otolaryngol Head Neck Surg 2015; 152: 279-283
    CrossrefGoogle Scholar
  • 14 Kirkegaard MM, Coupland SE, Prause JU et al. Malignant lymphoma of the conjunctiva. Surv Ophthalmol 2015; 60: 444-458
    CrossrefPubMedGoogle Scholar
  • 15 Ferreri AJ, Guidoboni M, Ponzoni M et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004; 96: 586-594
    CrossrefGoogle Scholar
  • 16 Ferreri AJ, Viale E, Guidoboni M et al. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol 2006; 17: 769-772
    CrossrefGoogle Scholar
  • 17 Theander E, Henriksson G, Ljungberg O et al. Lymphoma and other malignancies in primary Sjogrenʼs syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006; 65: 796-803
    CrossrefGoogle Scholar
  • 18 Aronow ME, Portell CA, Sweetenham JW et al. Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes. Ophthalmology 2014; 121: 334-341
    CrossrefGoogle Scholar
  • 19 Coupland SE, Foss HD, Hidayat AA et al. Extranodal marginal zone B cell lymphomas of the uvea: an analysis of 13 cases. J Pathol 2002; 197: 333-340
    CrossrefGoogle Scholar
  • 20 Mashayekhi A, Shields CL, Shields JA. Iris involvement by lymphoma: a review of 13 cases. Clin Experiment Ophthalmol 2013; 41: 19-26
    CrossrefGoogle Scholar
  • 21 Doycheva D, Zierhut M, Süsskind D et al. Diagnostik und Therapie der choroidalen Lymphome. Ophthalmologe 2015; 112: 217-222
    CrossrefGoogle Scholar
  • 22 Chan CC, Rubenstein JL, Coupland SE et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011; 16: 1589-1599
    CrossrefGoogle Scholar
  • 23 Sagoo MS, Mehta H, Swampillai AJ et al. Primary intraocular lymphoma. Surv Ophthalmol 2014; 59: 503-516
    CrossrefGoogle Scholar
  • 24 Mulay K, Narula R, Honavar SG. Primary vitreoretinal lymphoma. Indian J Ophthalmol 2015; 63: 180-186
    CrossrefGoogle Scholar
  • 25 Matsuo T, Ichimura K, Kubonishi S. Mantle cell lymphoma diagnosed by conjunctival salmon-pink lesion biopsy. J Clin Exp Hematop 2014; 54: 143-147
    CrossrefGoogle Scholar
  • 26 Kakkassery V, Stubiger N, Adamietz IA et al. [Lymphoma of the ocular adnexa]. Ophthalmologe 2015; 112: 210-216
    CrossrefGoogle Scholar
  • 27 Stubiger N, Kakkassery V, Gundlach E et al. [Diagnostics and treatment of primary vitreoretinal lymphoma]. Ophthalmologe 2015; 112: 223-230
    CrossrefGoogle Scholar
  • 28 Loriaut P, Charlotte F, Bodaghi B et al. Choroidal and adnexal extranodal marginal zone B-cell lymphoma: presentation, imaging findings, and therapeutic management in a series of nine cases. Eye (Lond) 2013; 27: 828-835
    CrossrefGoogle Scholar
  • 29 Polito E, Galieni P, Leccisotti A. Clinical and radiological presentation of 95 orbital lymphoid tumors. Graefes Arch Clin Exp Ophthalmol 1996; 234: 504-509
    CrossrefGoogle Scholar
  • 30 Newman JS, Francis IR, Kaminski MS et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-116
    CrossrefGoogle Scholar
  • 31 Hoffman PM, McKelvie P, Hall AJ et al. Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye (Lond) 2003; 17: 513-521
    CrossrefGoogle Scholar
  • 32 Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol 2004; 242: 901-913
    CrossrefGoogle Scholar
  • 33 Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med 2013; 15: 93-100
    Google Scholar
  • 34 Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. Retina 2011; 31: 435-440
    CrossrefGoogle Scholar
  • 35 Bonzheim I, Giese S, Deuter C et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood 2015; 126: 76-79
    CrossrefGoogle Scholar
  • 36 Tuo J, Shen D, Yang HH et al. Distinct microRNA-155 expression in the vitreous of patients with primary vitreoretinal lymphoma and uveitis. Am J Ophthalmol 2014; 157: 728-734
    CrossrefGoogle Scholar
  • 37 White LM, Schweitzer ME, Khalili K et al. MR imaging of primary lymphoma of bone: variability of T2-weighted signal intensity. Am J Roentgenol 1998; 170: 1243-1247
    CrossrefGoogle Scholar
  • 38 Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012; 380: 848-857
    CrossrefGoogle Scholar
  • 39 Sallak A, Besson FL, Pomoni A et al. Conjunctival MALT lymphoma: utility of FDG PET/CT for diagnosis, staging, and evaluation of treatment response. Clin Nucl Med 2014; 39: 295-297
    CrossrefGoogle Scholar
  • 40 Stafford SL, Kozelsky TF, Garrity JA et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol 2001; 59: 139-144
    CrossrefPubMedGoogle Scholar
  • 41 Regueiro CA, Valcarcel FJ, Romero J et al. Treatment of conjunctival lymphomas by beta-ray brachytherapy using a strontium-90-yttrium-90 applicator. Clin Oncol (R Coll Radiol) 2002; 14: 459-463
    CrossrefGoogle Scholar
  • 42 Heinz C, Merz H, Nieschalk M et al. Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland. Br J Ophthalmol 2007; 91: 1563-1564
    CrossrefGoogle Scholar
  • 43 Tuncer S, Tanyildiz B, Basaran M et al. Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience. Curr Eye Res 2015; 40: 780-785
    CrossrefGoogle Scholar
  • 44 Ferreri AJ, Govi S, Colucci A et al. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas. Ophthalmology 2011; 118: 24-28
    CrossrefGoogle Scholar
  • 45 Savino G, Battendieri R, Gari M et al. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. J Cancer Res Clin Oncol 2013; 139: 1251-1255
    CrossrefGoogle Scholar
  • 46 Ferreri AJ, Ponzoni M, Martinelli G et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. Haematologica 2005; 90: 1578-1579
    Google Scholar
  • 47 Ferreri AJ, Govi S, Pasini E et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 2012; 30: 2988-2994
    CrossrefGoogle Scholar
  • 48 Jusufbegovic D, Kim V, Char DH. Primary uveal lymphoma with epibulbar extension masquerading as an intraocular inflammation. Can J Ophthalmol 2015; 50: e24-e26
    CrossrefGoogle Scholar
  • 49 Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina 2009; 29: 129-132
    CrossrefGoogle Scholar
  • 50 Grimm SA, McCannel CA, Omuro AM et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group report. Neurology 2008; 71: 1355-1360
    CrossrefGoogle Scholar
  • 51 Bilsing B, Anger B, Meyer F. [Medical Rehabilitation in Gastrointestinal Oncology]. Zentralbl Chir 2015; 140: 382-389
    Artikel in Thieme ConnectGoogle Scholar
  • 52 Zeissig SR, Singer S, Koch L et al. [Utilisation of psycho-oncological services in hospitals and outpatient counselling centres by survivors of breast, colon and prostate cancer]. Psychother Psychosom Med Psychol 2015; 65: 177-182
    Artikel in Thieme ConnectGoogle Scholar
  • 53 Singer S, Danker H, Briest S et al. Effect of a structured psycho-oncological screening and treatment model on mental health in cancer patients (STEPPED CARE): study protocol for a cluster randomized controlled trial. Trials 2014; 15: 482
    CrossrefGoogle Scholar
  • 54 Baraniskin A, Kuhnhenn J, Schlegel U et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 2011; 117: 3140-3146
    CrossrefGoogle Scholar
  • 55 Baraniskin A, Kuhnhenn J, Schlegel U et al. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. J Neurooncol 2012; 109: 239-244
    CrossrefGoogle Scholar
  • 56 Riemens A, Bromberg J, Touitou V et al. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol 2015; 133: 191-197
    CrossrefGoogle Scholar
  • 57 Ben Abdelwahed R, Donnou S, Ouakrim H et al. Preclinical study of ublituximab, a glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci 2013; 54: 3657-3665
    CrossrefGoogle Scholar